A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of JS002 Prefilled Syringes(PFS) and Prefilled Autosyringes(AI) in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia
Latest Information Update: 12 Jan 2025
At a glance
- Drugs Ongericimab (Primary)
- Indications Hypercholesterolaemia; Hyperlipidaemia
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Junshi Biosciences
- 11 Oct 2024 According to Shanghai Junshi Biosciences media release, this study is led by Professor Shuiping ZHAO from the Second Xiangya Hospital of Central South University
- 11 Oct 2024 According to Shanghai Junshi Biosciences media release, National Medical Products Administration (NMPA) has approved new drug applications (NDA) for ongericimab injection for the treatment of primary hypercholesterolemia and mixed dyslipidemia, based on results from this study.
- 01 Sep 2024 Results published in the Nutrition, Metabolism and Cardiovascular Diseases